Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, by Drug Class (Glycopeptides and Lipoglycopeptides, Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, a

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, by Drug Class (Glycopeptides and Lipoglycopeptides, Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Methicillin-resistant staphylococcus aureus (MRSA) is an infection of the skin that occurs mostly in hospitals and healthcare facilities. It is treated with commonly used antibiotics and usually spreads from person to person by direct skin-to-skin contact. Physicians often find MRSA harder to treat than most other strains of staphylococcus aureus because it is sometimes resistant to commonly-used antibiotics such as methicillin. Some of the most commonly used antibiotics use for the treatment of MRSA include glycopeptides and lipoglycopeptides, oxazolidinones, lipopeptides, cephalosporin, and others. These drugs are used to kill or restrain Methicillin-resistant staphylococcus aureus infection.
Market Dynamics
Rising number of pipeline products, and increasing product launches & approval for the treatment of MRSA infection are some of the major factors responsible for the growth of global Methicillin-resistant staphylococcus aureus (MRSA) market. For instance, For instance, in 2018, Destiny Pharma received investigational new drug application from FDA for its new candidate, XF-73, a dicationic porphyrin molecule based nasal gel, to combat post-surgical infections of Methicillin-resistant Staphylococcus aureus (MRSA).
Key features of the study:
This report provides in-depth analysis of the global Methicillin-resistant staphylococcus aureus (MRSA) drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Methicillin-resistant staphylococcus aureus (MRSA) drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Merck & Co., Inc., Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Melinta Therapeutics, Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics Plc., Paratek Pharmaceuticals, Inc., Debiopharm International SA., Innovation Pharmaceuticals Inc., and Basilea Pharmaceutica Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global Methicillin-resistant staphylococcus aureus (MRSA) drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Methicillin-resistant staphylococcus aureus (MRSA) drugs market
Detailed Segmentation:
Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs market, By Drug Class:
Glycopeptides and Lipoglycopeptides
Oxazolidinones
Lipopeptides
Cephalosporin
Tetracycline
Others
Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs market, By Region:
North America
By Drug Class:
Glycopeptides and Lipoglycopeptides
Oxazolidinones
Lipopeptides
Cephalosporin
Tetracycline
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Class:
Glycopeptides and Lipoglycopeptides
Oxazolidinones
Lipopeptides
Cephalosporin
Tetracycline
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class:
Glycopeptides and Lipoglycopeptides
Oxazolidinones
Lipopeptides
Cephalosporin
Tetracycline
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Glycopeptides and Lipoglycopeptides
Oxazolidinones
Lipopeptides
Cephalosporin
Tetracycline
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class:
Glycopeptides and Lipoglycopeptides
Oxazolidinones
Lipopeptides
Cephalosporin
Tetracycline
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
Glycopeptides and Lipoglycopeptides
Oxazolidinones
Lipopeptides
Cephalosporin
Tetracycline
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Merck & Co., Inc. *
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Pfizer Inc.
AbbVie Inc.
Teva Pharmaceutical Industries Ltd.
Melinta Therapeutics, Inc.
Cumberland Pharmaceuticals Inc.
Nabriva Therapeutics Plc.
Paratek Pharmaceuticals, Inc.
Debiopharm International SA.
Innovation Pharmaceuticals Inc.
Basilea Pharmaceutica Ltd.
“*” marked represents similar segmentation in other categories in the respective section.